653. Multiple Myeloma: Clinical and Epidemiological: Poster II

Real world pharmacovigilance of BCMA targeted CAR T therapy in refractory multiplemyeloma A comparative analysis of idecabtagene vicleucel and ciltacabtagene autoleucel

The association between sglt 2 inhibitor use and progression from monoclonal gammopathy of undetermined significance to multiple myeloma in US veterans

Underexplored mutations in plasma cell myeloma

Survival outcomes and treatment patterns in primary and secondary plasma cell leukemia A multicenter retrospective cohort study

Impact of pre existing cardiovascular disease on inpatient arrhythmias following autologous stem cell transplantation in multiple myeloma A national inpatient sample database analysis

Cytokine release syndrome prophylaxis strategy with dipyrone in patients receiving bispecific Antibodies—Elranatamab teclistamab talquetamab and Epcoritamab—at a private hospital in southern Brazil Preliminary Results

Comparative analysis of next generation flow NGF and next generation sequencing based clonoseq for MRD detection in multiple myeloma using paired bone marrow samples

Determinants of renal recovery and survival in patients with myeloma presenting with high circulating free light chains and renal impairement

Incidence outcomes and economic burden of cytokine release syndrome and immune effector cell associated neurotoxicity syndrome in patients undergoing CAR T cell therapy for multiple myeloma

Feasibility of anti BCMA CAR T therapy in a middle income country

Serum free light chain escape before IMWG progression A predictive marker and a therapeutic opportunity

Defining functional high risk multiple myeloma in the era of modern induction therapy

Daratumumab provides equivalent survival benefits in first line and second line treatment of transplant ineligible multiple myeloma A computational analysis of Phase 3 trials in first line and second line settings

Liquid biopsy by analysis of circulating tumor cells hormonal and inflammatory biomarkers in plasma cell neoplasms at Fundacion Santa Fe de Bogota hospital

Individualized treatment risk stratification using histopathology based genomics prediction in multiple myeloma A multicenter Study in 1429 participants

Characterization of a population with newly diagnosed standard risk multiple myeloma by the 2025 ims IMWG definition with exceptional long term outcomes after fixed duration therapy

Anti CD38 immunotherapy assay and monitoring in patients with multiple myeloma A monocentric pilot study

Patient reported outcomes and actigraphy following in class transition iCT from parenteral bortezomib V to oral ixazomib in newly diagnosed multiple myeloma NDMM Subgroup analysis of US MM 6 by race ethnicity renal function and area income

Dynamic picture of refractoriness patterns of multiple myeloma patients at first relapse from 2019 to 2025 A real life multicentre analysis in Italy

Association of the easix score with survival and adverse outcomes in a large elderly hispanic cohort of patients with multiple myeloma

Impact of immunoglobulin supplementation on infection rates in myeloma patients receiving novel immunotherapies

Tracking peripheral residual disease in myeloma Clonotypic sequencing and mass spectrometry in the teclistamab era

Rebuilding immunity Kinetics and clinical impact of immune reconstitution after CAR T cell therapy in multiple myeloma

Serum BCMA sBCMA levels in plasma cell dyscrasias Insights from a south Indian prospective study

Infections following combined therapy with a GPRC5DxCD3 bispecific antibody talquetamab  and an interleukin 6 receptor inhibitor tocilizumab  in multiple myeloma patients

Systematic analysis of gene mutations in Chinese multiple myeloma patients

Factors impacting treatment choice with a CD38 antibody immunomodulator proteasome inhibitor and dexamethasone in first line multiple myeloma patients A real world US study

Simplified frailty score for patients with multiple myeloma undergoing autologous stem cell transplant

The novel ims IMWG high risk multiple myeloma criteria may omit individuals with renal impairment and adverse disease prognosis

Efficacy and safety of recombinant adjuvanted zoster vaccine in patients with monoclonal gammopathies A prospective study

Dynamic monitoring of circulating plasma cells in multiple myeloma A Prospective multicenter study in China

Isotype specific heavy light chain quantification identifies prognostic biomarkers after ARI0002h BCMA directed CAR T cell therapy in multiple myeloma

Interim results from a multicenter trial assessing the clinical relevance of copy number aberrations detected by a shallow whole genome sequencing analysis LeukoPrint  in multiple myeloma

Multiple myeloma with concomitant chronic lymphocytic leukemia Common or distinct clonal origin

Real world outcomes of newly diagnosed multiple myeloma patients in the veterans affairs healthcare system

First report of AI derived metrics from whole body MRI in patients with multiple myeloma reveals unique insights into body composition and changes on therapy

The treatment of transplant eligible primary plasmacell leukemia patients An italian real life Study

Impact of 1q gain amplification in multiple myeloma patients treated with daratumumab based regimens A retrospective single center study

Health care resource utilization in patients with multiple myeloma receiving bispecific antibody therapy with teclistamab A Medicare claims database analysis in the US